Navigation Links
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
Date:5/19/2009

INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Florida, May 29 through June 2, 2009.

The presentation for Semafore's vascular targeted pan-PI3K/mTOR inhibitor is scheduled as follows:

    Time:        Saturday, May 30, 2009: 8:00 a.m. - 12:00 p.m. EDT
    Poster       Phase I evaluation of SF1126 a vascular targeted PI3K
    Title:       inhibitor administered twice weekly IV in patients with
                 refractory solid tumors
    Presenter:   Elena G. Chiorean, MD
    Location:    Level 2 - West Hall C. Poster Session Track: #79
                 Developmental Therapeutics: Cytotoxic Chemotherapy; Poster
                 Board B19 (Abstract # 2558)

About SF1126

SF1126 is the only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment.

In preclinical xenograft models SF1126 has demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and has been shown to reverse resistance mediated through the PI3K/PTEN pathway.

About PI3 Kinase

Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of intracellular signal transduction and are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase signaling cascades can lead to cancer and aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors AKT and mTOR is also known to promote tumor cell survival, proliferation, and growth. Notably, dysregulation of PI3K signaling is thought to contribute to resistance to a variety of anticancer therapies. Thus, PI3K is considered a high value target in treating cancer.

About Semafore Pharmaceuticals, Inc.

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN inhibitors. The Company has successfully discovered and is developing a portfolio of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information see the company's web site at www.SemaforePharma.com.


'/>"/>
SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data
2. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
3. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
4. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
5. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
11. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... 2016  The blood testing market in ... Kalorama Information and The Freedonia Group in a recent ... testing.  The healthcare research firm said that ... collection stations and in improving testing at the provincial ... Blood Testing Market in China , ...
(Date:4/28/2016)... -- , Net Sales of $1.90 billion represent an ... year period, and an increase of 1.2% on an adjusted ... the first quarter were $0.52 reported, a decrease of 47.5% ... of 29.9% over the prior year period , The ... 2016 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... Pets bring laughter, ... token of appreciation, pet owners celebrate National Pet Week, which falls on the first ... remind pet owners to cherish the human-animal bond and recognize responsible pet ownership. Pet ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s Insight Behavioral Health Center ... disorders, has rebranded its eating disorder program under a new name: Eating Recovery Center, ... on May 16. , To celebrate, ERC Chicago will host a ribbon-cutting ceremony ...
(Date:5/2/2016)... ... , ... In honor of National Physical Fitness and Sports Month in May, ... fitness journey on social media. , The foot care company, which specializes in ... voucher each week during May to one winner. , “Whether the goal is to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, dentist in ... day treatments. In the past, many necessary dental treatments could require multiple appointments to ... anesthetic shots and extra chair time. Not only could this be inconvenient, but it ...
(Date:5/2/2016)... ... 02, 2016 , ... MedPro Waste Disposal, LLC (MedPro) is proud to announce ... its mail back service for an all-inclusive rate. MedPro Disposal President, Dan Hansen, says, ... to all of the clients in the country who are looking for an alternative ...
Breaking Medicine News(10 mins):